Trial reportNature2022
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Erratum issued Registry-linked trialOpen access · hybridAbstract readClinical Trial
In one paragraph
Trial report in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06365619 (Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma), which is not on this map. Cited by 191 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 8 pooled it
31.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Who cites it
191 citing papers in PubMed, 8 syntheses or guidelines pooled it, 317 citations in OpenAlex.
- Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis.JNCI cancer spectrum · 2026Pooled it
- Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Guideline
- The Safety and Efficacy of Anti-LAG-3 for Patients with Melanoma: A Systematic Review and Meta-analysis Study.Anti-cancer agents in medicinal chemistry · 2026Pooled it
- A comprehensive review and case series of adjuvant and neoadjuvant therapies in acral melanoma with emerging insights from CT DNA testing.Frontiers in oncology · 2025Pooled it
- The efficacy and safety of relatlimab/nivolumab combination therapy in patients with advanced melanoma: a systematic review.Archives of dermatological research · 2024Pooled it
- Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.Journal for immunotherapy of cancer · 2023Guideline
- Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.Nature cancer · 2026Trial
- Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.Nature medicine · 2025Trial
- Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.Nature medicine · 2025Trial
- Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.Journal for immunotherapy of cancer · 2025Trial
- Distinct CD8Cancer cell · 2025Trial
- Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.Nature medicine · 2025Trial
- Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Cancer cell · 2024Trial
- Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.Nature medicine · 2024Trial
- Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFNature medicine · 2024Trial
- Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8Cell · 2024Trial
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.Nature communications · 2024Trial
131 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
40 authors at 3 institutions in 1 country.
Rodabe N Amaria *Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rnamaria@mdanderson.org.ORCID http://orcid.org/0000-0001-6876-278X
Michael Postow *Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Elizabeth M Burton *Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael T TetzlaffDepartment of Pathology, The University of California San Francisco, San Francisco, CA, USA.
Merrick I RossDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.ORCID http://orcid.org/0000-0002-7787-0421
Carlos Torres-CabalaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7422-0661
Isabella C GlitzaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-4530-7765
Fei DuanDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Denái R MiltonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Klaus BusamDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-0888-9601
Lauren SimpsonDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer L McQuadeDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-2393-2172
Michael K WongDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey E GershenwaldDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
Jeffrey E LeeDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.ORCID http://orcid.org/0000-0001-6010-5590
Ryan P GoepfertDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emily Z KeungDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
Sarah B FisherDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
Allison Betof-WarnerDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0001-6422-2997
Alexander N ShoushtariDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-8065-4412
Margaret CallahanDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-9087-0012
Daniel CoitDepartment of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Edmund K BartlettDepartment of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Danielle BelloDepartment of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Parisa MomtazDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Courtney NicholasDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8596-0200
Aidi GuDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xuejun ZhangDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brinda Rao KoriviDepartment of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Madhavi PatnanaDepartment of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8135-8001
Sapna P PatelDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1339-1517
Adi DiabDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anthony LucciDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
Victor G PrietoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9204-7161
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0977-0912
James P AllisonDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Padmanee SharmaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4658-055X
Jennifer A WargoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.ORCID http://orcid.org/0000-0003-3438-7576
Charlotte AriyanDepartment of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hussein A TawbiDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1942-851X
The University of Texas MD Anderson Cancer Center · USMemorial Sloan Kettering Cancer Center · USUniversity of California, San Francisco · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Michael Jason de la Cruz · 1985 to 2026
$347.4MTRANSLATIONAL AND ANALYTICAL CHEMISTRY COREP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PETER W PISTERS · 1985 to 2026
$279.3MThe University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2019 to 2023
$10.3MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221703
Abstract
Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma
Indexed as
MelanomaNeoadjuvant TherapyNivolumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDrug Therapy, CombinationHumansImmune Checkpoint InhibitorsMacrophagesNeoplasm StagingSurvival RateAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsNivolumabrelatlimab
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06365619ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.